MedTrace Logo

To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

NCT00426608 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-09-11

No results posted yet for this study

Summary

A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).

Conditions

  • Depressive Disorder and Anxiety Disorders

Interventions

DRUG

metyrapone

Metyrapone will be available as 250 mg dose capsule.

DRUG

alprazolam

Alprazolam capsules will be available with dose strength of 0.25mg

DRUG

placebo

GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

DRUG

GSK561679

GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-06
Primary Completion
2007-01-08
Completion
2007-01-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426608 on ClinicalTrials.gov